174 related articles for article (PubMed ID: 38265672)
1. Efficacy and Safety of Re-administration of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) After EGFR-TKI-Induced Interstitial Lung Disease (CS-Lung-005).
Kanaji N; Ichihara E; Tanaka T; Ninomiya T; Kozuki T; Ishikawa N; Nishii K; Shoda H; Yamaguchi K; Kawakado K; Toyoda Y; Inoue M; Miyatake N; Watanabe N; Inoue T; Mizoguchi H; Komori Y; Kojima K; Kadowaki N
Lung; 2024 Feb; 202(1):63-72. PubMed ID: 38265672
[TBL] [Abstract][Full Text] [Related]
2. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
Kashiwabara K; Semba H; Fujii S; Tsumura S
Cancer Chemother Pharmacol; 2017 Apr; 79(4):705-710. PubMed ID: 28258422
[TBL] [Abstract][Full Text] [Related]
3. Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma.
Kodama H; Wakuda K; Yabe M; Nishioka N; Miyawaki E; Miyawaki T; Mamesaya N; Kawamura T; Kobayashi H; Omori S; Ono A; Kenmotsu H; Naito T; Murakami H; Endo M; Takahashi T
Invest New Drugs; 2021 Apr; 39(2):571-577. PubMed ID: 32955628
[TBL] [Abstract][Full Text] [Related]
4. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
5. Stepwise prolongation of overall survival from first to third generation EGFR-TKIs for EGFR mutation-positive non-small-cell lung cancer: the Tokushukai REAl-world Data project (TREAD 01).
Uryu K; Imamura Y; Shimoyama R; Mase T; Fujimura Y; Hayashi M; Ohtaki M; Otani K; Hibino M; Horiuchi S; Fukui T; Fukai R; Chihara Y; Iwase A; Yamada N; Tamura Y; Harada H; Shinozaki N; Tsuya A; Fukuoka M; Minami H
Jpn J Clin Oncol; 2024 Mar; 54(3):319-328. PubMed ID: 37997468
[TBL] [Abstract][Full Text] [Related]
6. Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?
Tamiya M; Tamiya A; Suzuki H; Moriizumi K; Nakahama K; Taniguchi Y; Kunimasa K; Kimura M; Inoue T; Kuhara H; Nishino K; Hirashima T; Atagi S; Imamura F; Kumagai T
Anticancer Res; 2019 Jul; 39(7):3923-3929. PubMed ID: 31262922
[TBL] [Abstract][Full Text] [Related]
7. EGFR-TKI rechallenge in patients with EGFR-mutated non-small-cell lung cancer who progressed after first-line osimertinib treatment: A multicenter retrospective observational study.
Araki T; Kanda S; Obara M; Agatsuma T; Kakizaki Y; Hama M; Yamamoto H; Takada M; Yamamoto M; Matsuo A; Kondo D; Komatsu M; Sonehara K; Tateishi K; Hanaoka M; Koizumi T
Respir Investig; 2024 Mar; 62(2):262-268. PubMed ID: 38245931
[TBL] [Abstract][Full Text] [Related]
8. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
Takeda M; Okamoto I; Nakagawa K
Lung Cancer; 2015 Apr; 88(1):74-9. PubMed ID: 25704957
[TBL] [Abstract][Full Text] [Related]
9. Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B).
Tsubata Y; Watanabe K; Saito R; Nakamura A; Yoshioka H; Morita M; Honda R; Kanaji N; Ohizumi S; Jingu D; Nakagawa T; Nakazawa K; Mouri A; Takeuchi S; Furuya N; Akazawa Y; Miura K; Ichihara E; Maemondo M; Morita S; Kobayashi K; Isobe T
Int J Clin Oncol; 2022 Jan; 27(1):112-120. PubMed ID: 34643820
[TBL] [Abstract][Full Text] [Related]
10. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
11. EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer.
Oshima Y; Tanimoto T; Yuji K; Tojo A
JAMA Oncol; 2018 Aug; 4(8):1112-1115. PubMed ID: 29327061
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of afatinib for the treatment of non-small-cell lung cancer following osimertinib-induced interstitial lung disease: A retrospective study.
Nasu S; Suzuki H; Shiroyama T; Tanaka A; Samejima Y; Kanai T; Noda Y; Morishita N; Okamoto N; Hirashima T
Invest New Drugs; 2020 Dec; 38(6):1915-1920. PubMed ID: 32542461
[TBL] [Abstract][Full Text] [Related]
13. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS;
N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359
[TBL] [Abstract][Full Text] [Related]
14. Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury.
Ohmori T; Yamaoka T; Ando K; Kusumoto S; Kishino Y; Manabe R; Sagara H
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33466795
[TBL] [Abstract][Full Text] [Related]
15. Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101).
Nishioka N; Imai H; Endo M; Notsu A; Doshita K; Igawa S; Yokouchi H; Ninomiya T; Tokito T; Soda S; Fujiwara T; Asao T; Nakamichi S; Kawamura T; Inomata M; Nakashima K; Ito K; Goto Y; Umeda Y; Hirai S; Ushio R; Yokoo K; Takeda T; Fukui T; Ishihara M; Osaki T; Kubo S; Fujiwara T; Yamamoto C; Tsuda T; Tamura N; Hosokawa S; Chihara Y; Ikeda S; Furuya N; Nakahara Y; Miura S; Okamoto H
Target Oncol; 2024 May; 19(3):423-433. PubMed ID: 38613731
[TBL] [Abstract][Full Text] [Related]
16. Safety of Readministration of EGFR-TKI After Onset of Interstitial Lung Disease in Advanced EGFR-Mutated NSCLC: A Systematic Review and Meta-Analysis.
Kashizaki F; Chen H; Miyasaka A; Tsuchiya N; Yamada C; Okazaki S; Kaneko M; Kano T; Kameda Y; Kikuchi A; Yumoto K; Osawa H; Koizumi H; Takahashi K; Kaneko T
Clin Lung Cancer; 2024 Jan; 25(1):e52-e57.e2. PubMed ID: 37932180
[TBL] [Abstract][Full Text] [Related]
17. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
[TBL] [Abstract][Full Text] [Related]
18. Overall Survival with Osimertinib in Untreated,
Ramalingam SS; Vansteenkiste J; Planchard D; Cho BC; Gray JE; Ohe Y; Zhou C; Reungwetwattana T; Cheng Y; Chewaskulyong B; Shah R; Cobo M; Lee KH; Cheema P; Tiseo M; John T; Lin MC; Imamura F; Kurata T; Todd A; Hodge R; Saggese M; Rukazenkov Y; Soria JC;
N Engl J Med; 2020 Jan; 382(1):41-50. PubMed ID: 31751012
[TBL] [Abstract][Full Text] [Related]
19. The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M.
Huang YH; Tseng JS; Hsu KH; Chen KC; Su KY; Yu SL; Chen JJW; Yang TY; Chang GC
Sci Rep; 2021 Jun; 11(1):12084. PubMed ID: 34103652
[TBL] [Abstract][Full Text] [Related]
20. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
